Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

prinomastat

A synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	AG3340
Chemical structure:	(3S)-N-hydroxy-2,2-dimethyl-4-{{4-(4-piridinyloxy)phenyl}sulfonyl}-3-thiomorpholinecarboxamide

prinomastat

Search NCI's Drug Dictionary